Phase II Results Investigating Nivolumab for Metastatic Renal Cell Carcinoma
the Cancer Therapy Advisor take:
A phase III trial recently published in the Journal of Clinical Oncology reviewed nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody that restores T-cell immune activity, for dose-response relationship, safety, and antitumor activity when given to patients with metastatic renal cell carcinoma.
The study randomly assigned patients with clear-cell metastatic renal cell carcinoma who had previously received treatment with agents that target the VEGF pathway to received nivolumab intravenously at a dose of 0.3 mg/kg, 2 mg/kg, or 10 mg/kg every 3 weeks. The study’s primary objective was to measure the dose-response relationship in terms of progression-free survival.
The study’s secondary objectives were safety, overall survival, and objective response rate. The study included 168 patients. Sixty patients were in the 0.3 mg/kg nivolumab cohort, 54 patients were in the 2 mg/kg nivolumab cohort, and 54 patients were in the 10 mg/kg nivolumab cohort. Within all of the cohorts, 118 patients had previously received one or more prior systemic regimen.
The median progression-free survival among the cohorts was 2.7 months, 4 months, and 4.2 months, respectively (P=0.9). Overall response rate among the cohorts was 20%, 22%, and 20%, respectively, and medial overall survival was 18.2 months (80% CI, 16.2 to 24.0 months), 25.5 months (80% CI, 19.8 to 28.8 months), and 24.7 months (80% CI, 15.3 to 26.0 months), respectively.
Adverse events were recorded and the most frequent was fatigue—19 patients (11%) experienced adverse events that were categorized as grade 3 or 4.
The researchers concluded that nivolumab showed a manageable safety profile and antitumor activity for all three dose administrations. There was no dose-response relationship identified in relation to progression-free survival. Researchers thus indicate that further phase III testing is warranted.
Nivolumab was given to patients with metastatic renal cell carcinoma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Immunotherapy in Glioblastoma: Peaks and Pits
- Opinion: Understanding the FDA's Take on Cannabidiol
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Polymorphism in HSD3B1 as a Potential Prognostic Biomarker in Prostate Cancer
- Opioid Use and Cancer
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk